Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
- Details
- Category: Novartis
Novartis has reported that new data with the eye drug Lucentis® (ranibizumab), first licensed in June 2006, is highlighted in a total of 209 abstracts at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week.
Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis® (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio (INR) control in patients with nonvalvular atrial fibrillation.
Funding boost for GSK's open innovation research into diseases affecting the developing world
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing world. The funding will move early-stage research to the next level, to find new medicines for diseases such as TB, malaria, Leishmaniasis and sleeping sickness.
Lundbeck is well on track to deliver on guidance for 2013
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 4,576 million corresponding to an increase of 21%. Profit from operations (EBIT) in the quarter increased 73% to DKK 1,526 million corresponding to an EBIT margin of 33%. The quarter is positively impacted by non-recurring items from milestones and divestiture of the mature US product-portfolio.
Bayer: Life Sciences off to a good start in anniversary year
- Details
- Category: Bayer
For the Bayer Group, the first quarter of 2013 was marked by the positive development of its Life Sciences businesses. "HealthCare and CropScience got off to a good start in our anniversary year. Our new pharmaceutical products especially grew at a dynamic pace," said Management Board Chairman Dr. Marijn Dekkers when the interim report for the first quarter was published.
Bristol-Myers Squibb reports first quarter 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported financial results for the first quarter of 2013, and confirmed GAAP EPS and non-GAAP EPS guidance ranges for 2013. Bristol-Myers Squibb posted first quarter 2013 net sales of $3.8 billion, a decrease of 27% compared to the same period a year ago, following the U.S. patent expiration of Avapro®/Avalide® in March 2012 and Plavix® in May 2012. Excluding Plavix and Avapro/Avalide, net sales grew by 10% compared to the first quarter of 2012.
AstraZeneca first quarter results 2013
- Details
- Category: AstraZeneca
AstraZeneca today announced that the revenue for the first quarter was $6,385 million, down 12 percent at constant exchange rates (CER). Losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada, were the key drivers for the revenue decline. Growth for Symbicort, Brilinta, Iressa and the inclusion of the Amylin diabetes products delivered more than $250 million of revenue growth at CER in the quarter.
More Pharma News ...
- Novartis delivered solid performance in the first quarter
- Abbott reports first-quarter 2013 results
- Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
- Roche Group posts strong sales growth in the first quarter
- Lundbeck announces positive results for Brintellix™ (vortioxetine)
- Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology
- MedImmune, AstraZeneca's biologics unit, acquires AlphaCore Pharma